Andrew Zorn

Andrew Zorn has a diverse and extensive work experience. Andrew is currently the Director of Business Development at Inotiv since April 2023. Prior to this, they were the Director of Business Development at TandemAI from December 2022 to March 2023. From July 2022 to December 2022, they worked as the Director of Business Development at AYOXXA Biosystems GmbH, where they implemented commercial strategies and established partnerships in the life science sector. Andrew also held multiple roles at PerkinElmer, Inc., including Life Science Business Segment Leader from December 2020 to July 2022, and Senior Applications Scientist from January 2020 to December 2020. Additionally, they worked as a Scientific Consultant at Cisbio Bioassays from December 2016 to December 2020. Prior to this, they had positions at AbbVie as an Associate Scientist and Biologist, and at the University of Rochester as a Neuroscience Intern.

Andrew Zorn is currently a candidate for a Doctor of Philosophy (PhD) degree in Pharmacology at Northeastern University, a program they have been enrolled in since 2019 and is expected to complete in 2022. Prior to pursuing their PhD, Andrew obtained a Master of Science (M.S.) degree in Pharmacology from Northeastern University, a program they completed between 2017 and 2019. Their education journey began at the State University of New York at Plattsburgh, where they obtained their Bachelor's Degree in Biochemistry, which they completed from 2006 to 2011.